CHA Biotech Wins AX One-Stop Voucher to Automate Regulatory Documentation
CHA Biotech said it was selected for South Korea’s MSIT “AX One-Stop Voucher” to invest 2.6 billion won in an AI-SaaS system that automates drafting and verification of cell-therapy regulatory documents, especially CMC. The project will run via a consortium with Naver Cloud, Persona AI, and MedAI Plus.





